Barclays lowered the firm’s price target on Beam Therapeutics (BEAM) to $25 from $31 and keeps an Equal Weight rating on the shares. The firm updated the company’s model post the Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics Reports Strong Q1 2025 Progress
- Beam Therapeutics reports Q1 EPS ($1.24), consensus ($1.17)
- Beam Therapeutics sees cash runway into 2028
- JPMorgan biotech/Euro pharma analysts hold analyst/industry conference call
- Cathie Wood’s ARK Investment buys 135K shares of Beam Therapeutics today